Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests admilparant in adults with idiopathic pulmonary fibrosis

Compares admilparant with placebo in adults with idiopathic pulmonary fibrosis, a lung scarring disease.

Key facts

Who runs it
Bristol-Myers Squibb Services Unlimited Company
Where
Kortrijk, Leuven, Liège, Sint-Lambrechts-Woluwe, and Yvoir, BelgiumSee the 5 sitesAlso in 14 other countries, 89 sites
Trial code
Registry title
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Status
Recruiting
Phase
Phase 3
People taking part
239 people, planned
Started
24 Jun 2024
Expected to end
4 Jun 2027
Type of study
Interventional
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with idiopathic pulmonary fibrosis (IPF), a scarring lung disease. It compares admilparant (BMS-986278) with a placebo.

Age
40 years or older
Sex
Women and men can join.
Disease stage
IPF diagnosed within 7 years before screening, confirmed by a chest HRCT scan showing usual interstitial pneumonia.
Earlier treatment
If taking pirfenidone or nintedanib, the dose must have been stable for at least 90 days before screening. If not taking them, the person must not have had either in the 28 days before screening.

Main reasons for not taking part

  • Stroke or transient ischemic attack within 3 months before screening
  • Symptoms of heart failure at rest
  • Current cancer, or earlier cancer with less than 2 years free of recurrence
  • Interstitial lung disease with a known primary cause, such as hypersensitivity pneumonitis, autoimmune-related ILD or sarcoidosis

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Subjects with IPF aged ≥ 40 years at the time of signing the informed consent
  • Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia
  • If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening
  • If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening
  • Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test at screening and predose
  • Men who are sexually active with women of childbearing potential agree to use male barrier contraception

Who cannot take part

  • History of stroke or transient ischemic attack within 3 months prior to screening
  • Exhibit symptoms of heart failure at rest
  • Participants who have: 1) a current malignancy, 2) a previous malignancy with less than 2 years free of recurrence; 3) a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be ruled out
  • Interstitial Lung Disease (ILD) associated with known primary causes (eg.hypersensitivity pneumonitis,autoimmune associated ILD,sarcoidosis,etc.)

Where in Belgium

Also in 14 other countries, 89 sites

  • Algemeen Ziekenhuis GroeningeKortrijk, BelgiumNo longer taking part
  • UZ LeuvenLeuven, BelgiumNo longer taking part
  • CHU de LiègeLiège, BelgiumNo longer taking part
  • Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumNo longer taking part
  • Chu Ucl NamurYvoir, BelgiumNo longer taking part

About the trial

What the trial wants to find out

To evaluate the efficacy of admilparant compared to placebo (PBO) in demonstrating improvement in absolute change in Forced Vital Capacity (FVC) from baseline at Week 52.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Plain-language title
Tests admilparant in adults with idiopathic pulmonary fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 September 2026